Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.

Leisch M, Egle A, Greil R.

Future Oncol. 2019 Jan;15(2):109-120. doi: 10.2217/fon-2018-0492. Epub 2018 Aug 16. Review.

PMID:
30111169
2.

Improved pharmacokinetic profile of lipophilic anti-cancer drugs using ανβ3-targeted polyurethane-polyurea nanoparticles.

Rocas P, Fernández Y, García-Aranda N, Foradada L, Calvo P, Avilés P, Guillén MJ, Schwartz S Jr, Rocas J, Albericio F, Abasolo I.

Nanomedicine. 2018 Feb;14(2):257-267. doi: 10.1016/j.nano.2017.10.009. Epub 2017 Nov 7.

PMID:
29127040
3.

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

van Andel L, Rosing H, Fudio S, Avilés P, Tibben MM, Gebretensae A, Schellens JHM, Beijnen JH.

J Pharm Biomed Anal. 2017 Oct 25;145:137-143. doi: 10.1016/j.jpba.2017.06.013. Epub 2017 Jun 21.

PMID:
28662481
4.

Plitidepsin: design, development, and potential place in therapy.

Alonso-Álvarez S, Pardal E, Sánchez-Nieto D, Navarro M, Caballero MD, Mateos MV, Martín A.

Drug Des Devel Ther. 2017 Jan 19;11:253-264. doi: 10.2147/DDDT.S94165. eCollection 2017. Review.

5.

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

van Andel L, Fudio S, Rosing H, Munt S, Miguel-Lillo B, González I, Tibben MM, de Vries N, de Vries Schultink AHM, Schellens JHM, Beijnen JH.

Invest New Drugs. 2017 Oct;35(5):589-598. doi: 10.1007/s10637-017-0432-5. Epub 2017 Jan 23.

PMID:
28111728
6.

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria JC.

Anticancer Drugs. 2017 Mar;28(3):341-349. doi: 10.1097/CAD.0000000000000457.

PMID:
27977433
7.

Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.

Losada A, Muñoz-Alonso MJ, García C, Sánchez-Murcia PA, Martínez-Leal JF, Domínguez JM, Lillo MP, Gago F, Galmarini CM.

Sci Rep. 2016 Oct 7;6:35100. doi: 10.1038/srep35100.

8.

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC.

Anticancer Drugs. 2016 Nov;27(10):1021-7. doi: 10.1097/CAD.0000000000000409.

PMID:
27610894
9.

Cellular Uptake and Cytotoxic Effect of Epidermal Growth Factor Receptor Targeted and Plitidepsin Loaded Co-Polymeric Polymersomes on Colorectal Cancer Cell Lines.

Goñi-de-Cerio F, Thevenot J, Oliveira H, Pérez-Andrés E, Berra E, Masa M, Suárez-Merino B, Lecommandoux S, Heredia P.

J Biomed Nanotechnol. 2015 Nov;11(11):2034-49.

PMID:
26554161
10.

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo.

Borjan B, Steiner N, Karbon S, Kern J, Francesch A, Hermann M, Willenbacher W, Gunsilius E, Untergasser G.

BMC Cancer. 2015 Oct 19;15:738. doi: 10.1186/s12885-015-1729-4.

11.

Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study.

Toulmonde M, Le Cesne A, Piperno-Neumann S, Penel N, Chevreau C, Duffaud F, Bellera C, Italiano A.

Ann Oncol. 2015 Jul;26(7):1465-70. doi: 10.1093/annonc/mdv195. Epub 2015 Jun 3.

12.

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.

Pardanani A, Tefferi A, Guglielmelli P, Bogani C, Bartalucci N, Rodríguez J, Extremera S, Pérez I, Alfaro V, Vannucchi AM.

Blood Cancer J. 2015 Mar 13;5:e286. doi: 10.1038/bcj.2015.5.

13.

Enhanced in vivo therapeutic efficacy of plitidepsin-loaded nanocapsules decorated with a new poly-aminoacid-PEG derivative.

Lollo G, Hervella P, Calvo P, Avilés P, Guillén MJ, Garcia-Fuentes M, Alonso MJ, Torres D.

Int J Pharm. 2015 Apr 10;483(1-2):212-9. doi: 10.1016/j.ijpharm.2015.02.028. Epub 2015 Feb 11.

PMID:
25681727
14.

Cyclic depsipeptides as potential cancer therapeutics.

Kitagaki J, Shi G, Miyauchi S, Murakami S, Yang Y.

Anticancer Drugs. 2015 Mar;26(3):259-71. doi: 10.1097/CAD.0000000000000183. Review.

PMID:
25419631
15.

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.

Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL.

Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24. Review.

16.

Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.

Galmarini CM, D'Incalci M, Allavena P.

Mar Drugs. 2014 Jan 27;12(2):719-33. doi: 10.3390/md12020719. Review.

17.

Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model.

Oliveira H, Thevenot J, Garanger E, Ibarboure E, Calvo P, Aviles P, Guillen MJ, Lecommandoux S.

Pharm Res. 2014 Apr;31(4):983-91. doi: 10.1007/s11095-013-1220-3. Epub 2013 Nov 28.

PMID:
24287622
18.

Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.

Plummer R, Lorigan P, Brown E, Zaucha R, Moiseyenko V, Demidov L, Soriano V, Chmielowska E, Andrés R, Kudryavtseva G, Kahatt C, Szyldergemajn S, Extremera S, de Miguel B, Cullell-Young M, Calvert H.

Br J Cancer. 2013 Sep 17;109(6):1451-9. doi: 10.1038/bjc.2013.477. Epub 2013 Aug 29.

19.

c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity.

Muñoz-Alonso MJ, Álvarez E, Guillén-Navarro MJ, Pollán M, Avilés P, Galmarini CM, Muñoz A.

Mar Drugs. 2013 May 21;11(5):1677-92. doi: 10.3390/md11051677.

20.

Kinase inhibitors of marine origin.

Bharate SB, Sawant SD, Singh PP, Vishwakarma RA.

Chem Rev. 2013 Aug 14;113(8):6761-815. doi: 10.1021/cr300410v. Epub 2013 May 16. Review. No abstract available.

PMID:
23679846

Supplemental Content

Loading ...
Support Center